{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:43:33Z","timestamp":1787953413057,"version":"build-2784847793"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thermal injuries lead to a deficiency in one\u2019s natural, protective barrier, resulting in increased susceptibility to pathogens, and often require multiple courses of broad-spectrum antibiotics. Eravacycline (ERA) has shown adequate in vitro activity against multiple multi-drug resistant (MDR) pathogens including Acinetobacter sp. Due to the increasing prevalence of MDR bacteria and the heightened susceptibility of patients with burns to infection, studies are needed to examine the clinical effect of eravacycline in this population. The objective of this retrospective, case-control study was to compare the outcomes of patients with thermal injuries treated with eravacycline versus a matched control for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients with thermal injury admitted to an American Burn Associated-verified burn center from May 1, 2019 to July 31, 2022, who received eravacycline, were randomly matched 4:1 to a historical cohort using a previously established, de-identified dataset of patients treated with colistimethate sodium (CMS) in the same burn center (March 1, 2009 to March 31, 2014), based on % total body surface area (%TBSA), age, and CRAB. A composite favorable outcome was defined as 30-day survival, completion of the course, lack of 14-day recurrence, and lack of acute kidney injury (AKI). Treatment with eravacycline over CMS was not more or less likely to be associated with a favorable response [odds ratio (95% confidence interval), 2.066 (0.456\u20139.361), P = .347]. Patients treated with CMS had nearly 9-fold higher odds of new-onset AKI versus ERA [8.816 (0.911\u201385.308), P = .06]. Adverse events were uncommon in the ERA group. There was no difference in mortality.<\/jats:p>","DOI":"10.1093\/jbcr\/irad183","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T22:53:46Z","timestamp":1700088826000},"page":"487-492","source":"Crossref","is-referenced-by-count":9,"title":["A Retrospective Case-Control Study of Eravacycline for the Treatment of Carbapenem-Resistant Acinetobacter Infections in Patients With Burn Injuries"],"prefix":"10.1093","volume":"45","author":[{"given":"Connor","family":"Alexander","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Regional One Health , Memphis, TN 38103 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Regional One Health , Memphis, TN 38103 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"issue":"5","key":"2024030419494368300_CIT0001","first-page":"344","article-title":"The antibiotic resistance crisis: part 2: management strategies and new agents","volume":"40","author":"Ventola","year":"2015","journal-title":"P T"},{"key":"2024030419494368300_CIT0002","first-page":"291","article-title":"Multidrug resistant acinetobacter","volume-title":"J Glob Infect Dis","author":"Manchanda","year":"2010"},{"key":"2024030419494368300_CIT0003","first-page":"687","article-title":"Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment","volume-title":"Clin Microbiol Infect","author":"Cisneros","year":"2002"},{"issue":"Suppl 7","key":"2024030419494368300_CIT0004","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant Gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024030419494368300_CIT0005","first-page":"281","article-title":"Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay","volume-title":"Am J Med","author":"Fagon","year":"1993"},{"key":"2024030419494368300_CIT0006","author":"CDC","year":"2019"},{"key":"2024030419494368300_CIT0007","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024030419494368300_CIT0008","first-page":"315","article-title":"Eravacycline: a review in complicated intra-abdominal infections [published correction appears in Drugs 2019 Apr 11]","volume-title":"Drugs","author":"Scott","year":"2019"},{"key":"2024030419494368300_CIT0009","first-page":"567","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume-title":"Drugs","author":"Zhanel","year":"2016"},{"key":"2024030419494368300_CIT0010","first-page":"e01699","article-title":"In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume-title":"Antimicrob Agents Chemother","author":"Morrissey","year":"2020"},{"key":"2024030419494368300_CIT0011","first-page":"224","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume-title":"JAMA Surg","author":"Solomkin","year":"2017"},{"key":"2024030419494368300_CIT0012","first-page":"921","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume-title":"Clin Infect Dis","author":"Solomkin","year":"2019"},{"key":"2024030419494368300_CIT0013","volume-title":"Lexi-Drugs","author":"Eravacycline","year":"2022"},{"key":"2024030419494368300_CIT0014","first-page":"546","article-title":"Drug regimens of novel antibiotics in critically ill patients with varying renal functions: a rapid review","volume-title":"Antibiotics (Basel)","author":"Gorham","year":"2022"},{"key":"2024030419494368300_CIT0015","first-page":"e0047922","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii","volume-title":"Microbiol Spectr","author":"Alosaimy","year":"2022"},{"key":"2024030419494368300_CIT0016","first-page":"538","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume-title":"Clin Microbiol Rev","author":"Peleg","year":"2008"},{"key":"2024030419494368300_CIT0017","first-page":"759","article-title":"Analysis of ceftazidime\/avibactam use for treating carbapenem-resistant infections in critically ill patients with thermal or inhalation injuries","volume-title":"J Burn Care Res","author":"Martin","year":"2022"},{"key":"2024030419494368300_CIT0018","first-page":"2130","article-title":"Bacterial infections after burn injuries: impact of multidrug resistance","volume-title":"Clin Infect Dis","author":"Lachiewicz","year":"2017"},{"key":"2024030419494368300_CIT0019","first-page":"1453","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume-title":"Lancet","author":"von Elm","year":"2007"},{"key":"2024030419494368300_CIT0020","first-page":"819","article-title":"AKI in the ICU: definition","volume-title":"Kidney Int","author":"Singbartl","year":"2012"},{"key":"2024030419494368300_CIT0021","first-page":"376","article-title":"Acute kidney injury in burn patients: clinically significant over the initial hospitalization and 1 year after injury: an original retrospective cohort study","volume-title":"Ann Surg","author":"Thalji","year":"2017"},{"issue":"4","key":"2024030419494368300_CIT0022","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1046\/j.1523-1755.2001.00947.x","article-title":"Type of vascular access and mortality in US hemodialysis patients","volume":"60","author":"Dhingra","year":"2001","journal-title":"Kidney Int"},{"key":"2024030419494368300_CIT0023","first-page":"88","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese","volume-title":"Clin Infect Dis","author":"Nation","year":"2014"},{"key":"2024030419494368300_CIT0024","first-page":"ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume-title":"Open Forum Infect Dis","author":"Alosaimy","year":"2020"},{"key":"2024030419494368300_CIT0025","first-page":"ofaa071","article-title":"Real world multi-center experience with eravacycline for complicated infections","author":"Alosaimy","year":"2020"},{"key":"2024030419494368300_CIT0026","first-page":"S651","article-title":"Early real-world evidence in the use of eravacycline for the management of draconian infections","author":"Carr","year":"2020"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irad183\/53845134\/irad183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/45\/2\/487\/56828187\/irad183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/45\/2\/487\/56828187\/irad183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T19:50:31Z","timestamp":1709581831000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/45\/2\/487\/7424575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11,16]]},"published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/irad183","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,11,16]]}}}